Coccidioidomycosis Clinical Trial
Official title:
SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
The purpose of this study is to determine how safe, effective, and well tolerated a new investigational antifungal drug, SUBA-itraconazole, is for patients who have been previously treated with fluconazole and have had either an insufficient response to treatment with fluconazole or a negative reaction to fluconazole preventing their further treatment with it.
This is a prospective, multi-center, open-label study involving subjects with proven or probable coccidioidomycosis refractory to fluconazole therapy following >40 days of treatment or subjects with proven or probable coccidioidomycosis who are intolerant to fluconazole. The availability "Super Bioavailability" (SUBA) itraconazole 65 mg capsules with twice-daily dosing options with improved pharmacokinetics and lack of food or acidity requirements offers a substantial opportunity to improve the treatment of subjects with coccidioidomycosis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04208321 -
Safety and Pharmacokinetics of VT-1598
|
Phase 1 | |
| Terminated |
NCT00614666 -
Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02190266 -
Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
|
||
| Completed |
NCT00796809 -
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
|
N/A | |
| Withdrawn |
NCT02908334 -
Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis
|
Phase 2 | |
| Completed |
NCT00423267 -
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00690092 -
A Multi-center Study of Spherule-Derived Coccidioidin
|
Phase 3 | |
| Completed |
NCT03908632 -
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
|
||
| Terminated |
NCT02663674 -
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
|
Phase 4 | |
| Terminated |
NCT03618992 -
Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment
|
N/A | |
| Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 | |
| Completed |
NCT00002325 -
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
|
N/A |